

Dr. Joseph Vincent Thakuria, MD, MMSc

BIO:

Dr. Thakuria is a Harvard Medical School Clinical Scholar and medical geneticist with faculty appointments at Massachusetts General Hospital and Harvard Medical School where he has over 10 years of clinical experience. He is an internationally recognized expert on clinical interpretation of genomic and other “-omic” datasets, as well as an expert on various DNA sequencing platforms - specifically next generation sequencing - and varied applications. Dr. Thakuria was co-investigator and Medical Director of the Personal Genome Project (PGP) – a Harvard Medical School study approved for enrollment of 100,000 participants for comprehensive sequencing, phenotyping, tissue collection, generation of individualized adult stem cell lines, and biobanking. During his medical and biochemical genetics residency/fellowship at Harvard Medical School, Dr. Thakuria identified a new syndrome of developmental delay with Wolf-Parkinson White arrhythmia and discovered the causative gene.

He is the author of the chapter, “Clinical Interpretation of Genomic Data” in the American College of Physicians textbook, “Clinical Genomics,” and has authored publications of his medical genomic analyses in several high-impact journals including Nature, Science, and Lancet.

Dr. Thakuria is also a serial biotech entrepreneur and is an original founder and served as Chief Medical Officer for 3 successful, Boston-based, biotech start-ups, including Veritas Genetics, a CLIA /CAP - certified, genetics diagnostic laboratory which was cited in MIT Technology Review’s list of 50 Smartest Companies of 2016 and 2017. His latest(4th) biotech, Galactus Bioengineering and Biolistics, is focused on the development of new classes of drugs derived from both natural and genetically engineered medicinal plants.

Dr. Thakuria has been an invited participant in NIH NHLBI and NHGRI Working Groups to develop consensus statements on the return of genomic results to research participants. He also assists in the review of allocation of inpatient and outpatient resources for clinical genetic/genomic trials conducted system-wide across Harvard affiliated hospitals through his involvement in the Harvard Catalyst Clinical Research Center Protocol Review Committee.